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NOX enzymes are major ROS generators in pathological states and represent a promising pharmacological
target. In this issue of Chemistry & Biology, Smith and colleagues developed an original and elegant cell-free
assay to identify specific Nox2 inhibitors in a high throughput manner.A major breakthrough in redox biology
was made at the beginning of 21st century
when it was discovered that the NADPH
oxidase of the phagocyte (now known as
NOX2) was only one member of a whole
family of transmembrane proteins cata-
lyzing the production of reactive oxygen
species (ROS) in specific cell types. This
family comprises seven members of
enzymes (NOX1–NOX5 and DUOX1 and
2), which are major ROS generators in
both in physiological and pathological
conditions.
Excess of ROS is a hallmark of
numerous diseases and antioxidantmole-
cules have been extensively used as
treatments to neutralize ROS. Unfortu-
nately, this approach has shown little
medical benefit, probably because anti-
oxidants can act to decrease ROS levels
only once ROS have been produced.
Targeting the source of ROS, such as
NOX enzymes, has far more potential for
a pharmacological strategy as it prevents
ROS generation. Developing drugs that
act specifically on a particular isoform of
NOX would be an even more refined
treatment with fewer unwanted effects.
Targeting individual isoforms is conceiv-
able as, in spite of high structural similar-
ities, NOX isoforms differ in their mode
of activation.
Usual approaches to identify NOX
inhibitors are based on detection of
NOX-derived ROS using colorimetric,
luminescent, or fluorescent probes in
whole cells or in so-called semi recombi-
nant systems consisting of purified NOX-
containing membranes to which NADPH,
FAD, and recombinant cytosolic factors
are added. However, although straightfor-
ward, this approach shows a number of
limitations: (1) ROS are extremely reactive
molecules and the probes used to detect664 Chemistry & Biology 19, June 22, 2012 ªthem are prone to artifacts; (2) NOX
enzymes are not the sole source of ROS
in cells and membrane preparations; and
(3) more importantly these methods do
not discriminate between antioxidant
molecules (ROS scavengers) and real
inhibitors, i.e., compounds, that are able
to block NOX-derived ROS generation
by direct interaction with the enzyme (for
review, see Jaquet et al., 2009).
In this context, the study by Smith et al.
(2012) in this issue of Chemistry & Biology
is exemplary. In order to screen a chemi-
cally diverse library, they developed a
completely recombinant system not
based on NOX2 activity, but on the
blockade of the binding of cytosolic
subunits necessary for its activation.
The catalytic core of the NOX2 complex
is formed of a transmembrane protein
containing two heme molecules and
the binding sites for NADPH and FAD
(NOX2) as well as the transmembrane
protein p22phox. In order to catalyze
ROS production, NOX2 requires activa-
tion, in a process involving phosphory-
lation and translocation of cytosolic
subunits rac, p67phox, p40phox, and
p47phox (Figure 1A). In particular, the
interaction between a groove formed by
a tandem Src homology 3 (SH3) domain
of p47phox and a proline rich region of
p22phox is critical. This complex has
been crystallized and characterized both
in term of structure (Groemping et al.,
2003) and function (Sumimoto et al.,
1996) (Figure 1B).
This study by Smith et al. (2012) is the
first example of rational drug discovery
based on available structural information
on known binding pocket of the NOX2
complex. The assay consists of measur-
ing changes in fluorescence polarization
when a peptide containing the proline2012 Elsevier Ltd All rights reservedrich region of p22phox labeled with a fluo-
rescent molecule (rhodamine) interacts
with a recombinant protein encompass-
ing the tandem SH3 domain of p47phox
(Figure 1C). It was developed in a high
throughput screening format and requires
only minute amount of material. Selected
hits were validated in functional assays
to confirm that they in fact did block
NOX2.
Ebselen and a close analog named
Thr101 were among the most promising
molecules. This finding must have come
as a surprise, because ebselen is a
renowned antioxidant molecule! Ebselen
is a synthetic selenium compound
first described as a potent antioxidant
with glutathione peroxidase-like activity
(Mu¨ller et al., 1984). However, the current
study convincingly demonstrates that
ebselen is a bona fide NOX2 inhibitor,
confirming observations made more than
twenty years ago (Cotgreave et al., 1989;
Wakamura et al., 1990).
Although ebselen is potently inhibiting
NOX2, it is known to have numerous other
pharmacological effects, and the specific
disruption of p22phox-p47phox complex
might only be part of its effect on NOX2
as it also potently inhibited NOX5, an iso-
form completely independent of cytosolic
subunits. However, the other analogs
tested in this study show a strong correla-
tion between functional and binding
assays as well as lower potency on NOX5.
In many instances, it may be an advan-
tage to use molecules with multiple
modes of action for complex diseases
and the one drug-one target paradigm
promoted by the pharmaceutical industry
appears to bemore of a ‘‘holy grail’’ rather
than a biological reality. Nevertheless, the
protective action of ebselen in patholo-
gies where oxidative stress plays a key
Figure 1. Strategy for the Identification of Specific NOX2 Inhibitors
(A) The NOX2 complex requires the binding of cytosolic subunits for ROS (superoxide anion) generation.
(B) The rationale for identifying NOX2 inhibitors is based on the fact that NOX2 activation is fully dependent
on the binding of a tandem SH3 domain of p47phox to a proline rich (PRR) region of p22phox.
(C) In this study, the binding of p22phox-p47phox complex was reproduced in vitro. High fluorescence
polarization is measured when a rhodamine labeled peptide encompassing the PRR of p22phox binds
to a recombinant protein comprising the tandem SH3 domain of p47phox fused to glutathione-S trans-
ferase (GST). Small molecules like ebselen or Thr101 interfering with this interaction induce a change in
fluorescence polarization and were identified as hits in the HTS.
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hearing loss, should therefore be consid-
ered not only in the context of its antioxi-
dant role, but also in light of its potent
inhibitory action on NOX enzymes.In conclusion, the present description
of a cell-free high throughput screen
represents a milestone for the develop-
ment of NOX inhibitors jointly with the
efforts of the pharmaceutical industryChemistry & Biology 19, June 22, 2012(Gaggini et al., 2011; Laleu et al., 2010).
Furthermore, as the crystal structure of
the p47phox tandem SH3 domain with
the proline rich peptide is known, the
way is open for computer-assisted drug
design.
Discovering novel small molecules
NOX2 inhibitors will be extremely valuable
for numerous indications, in particular for
central nervous disorders where NOX2
plays a key regulatory role in neuroinflam-
matory and psychotic diseases (Sorce
et al., 2012).REFERENCES
Cotgreave, I.A., Duddy, S.K., Kass, G.E., Thomp-
son, D., and Molde´us, P. (1989). Biochem. Phar-
macol. 38, 649–656.
Gaggini, F., Laleu, B., Orchard,M., Fioraso-Cartier,
L., Cagnon, L., Houngninou-Molango, S., Gradia,
A., Duboux, G., Merlot, C., Heitz, F., et al. (2011).
Bioorg. Med. Chem. 19, 6989–6999.
Groemping, Y., Lapouge, K., Smerdon, S.J., and
Rittinger, K. (2003). Cell 113, 343–355.
Jaquet, V., Scapozza, L., Clark, R.A., Krause, K.H.,
and Lambeth, J.D. (2009). Antioxid. Redox Signal.
11, 2535–2552.
Laleu, B., Gaggini, F., Orchard,M., Fioraso-Cartier,
L., Cagnon, L., Houngninou-Molango, S., Gradia,
A., Duboux, G., Merlot, C., Heitz, F., et al. (2010).
J. Med. Chem. 53, 7715–7730.
Mu¨ller, A., Cadenas, E., Graf, P., and Sies, H.
(1984). Biochem. Pharmacol. 33, 3235–3239.
Smith, S.M.E., Min, J., Ganesh, T., Diebold, B.,
Kawahara, T., Zhu, Y., McCoy, J., Sun, A., Snyder,
J.P., Fu, H., et al. (2012). Chem. Biol. 19, this issue,
752–763.
Sorce, S., Krause, K.H., and Jaquet, V. (2012). Cell.
Mol. Life Sci.
Sumimoto, H., Hata, K., Mizuki, K., Ito, T., Kage, Y.,
Sakaki, Y., Fukumaki, Y., Nakamura, M., and
Takeshige, K. (1996). J. Biol. Chem. 271, 22152–
22158.
Wakamura, K., Ohtsuka, T., Okamura, N., Ishiba-
shi, S., and Masayasu, H. (1990). J. Pharmacobio-
dyn. 13, 421–425.ª2012 Elsevier Ltd All rights reserved 665
